Report
HEOR Value Demonstration and Evidence Generation Challenges
Interest in the field of health economics and outcomes research (HEOR) has grown exponentially as healthcare systems seek to provide the best possible health outcomes at affordable ...
White Paper
Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program
This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what shoul ...
White Paper
Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs
This white paper looks at how rebates to PBMs relate to drug prices from two perspectives: how they are supposed to work versus what actually happens. ...
White Paper
Growing Attention Being Paid To Pharma Company Rebates And Discounts
Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...
White Paper
Perspectives On Pharma Company Use Of Open Payments Data
This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...
White Paper
Pricing and Market Effects of Biosimilar Entry in the US
This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...
White Paper
Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies
President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...
White Paper
Econometric Analysis Of Biopharmaceutical Transfer Pricing
The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...
White Paper
The Relationship Between Drug Price Controls And Patient Health Outcomes
No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...
White Paper
The Pricing Challenge Of Pharma’s Shift To Specialty Medicines
The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift ...